These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9311269)

  • 21. Graft-versus-leukemia effects from donor lymphocyte infusion after nonmyeloablative allogeneic bone marrow transplantation in mice.
    Du B; Li DP; Xu KL; Pan XY
    Chin Med J (Engl); 2005 Mar; 118(6):474-9. PubMed ID: 15788128
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
    Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
    Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Cyclosporine-induced graft-versus-host disease in a syngeneic bone marrow transplantation].
    Hashimoto S; Kawano E; Hirasawa A; Morio S; Aotuka N; Nakamura H; Oh H; Asai T; Yoshida S; Ishii G
    Rinsho Ketsueki; 1993 Jan; 34(1):34-8. PubMed ID: 8450605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Study of experimental mixed bone marrow transplantation].
    Luo H; Yang P; He F
    Zhonghua Xue Ye Xue Za Zhi; 1998 Aug; 19(8):418-21. PubMed ID: 11189509
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of HLA allele and killer immunoglobulin-like receptor ligand matching on clinical outcome in leukemia patients undergoing transplantation with T-cell-replete marrow from an unrelated donor.
    Morishima Y; Yabe T; Matsuo K; Kashiwase K; Inoko H; Saji H; Yamamoto K; Maruya E; Akatsuka Y; Onizuka M; Sakamaki H; Sao H; Ogawa S; Kato S; Juji T; Sasazuki T; Kodera Y;
    Biol Blood Marrow Transplant; 2007 Mar; 13(3):315-28. PubMed ID: 17317585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of a graft-versus-leukemia reaction by cyclosporin A withdrawal as immunotherapy for leukemia relapsing after allogeneic bone marrow transplantation.
    Elmaagacli AH; Beelen DW; Trenn G; Schmidt O; Nahler M; Schaefer UW
    Bone Marrow Transplant; 1999 Apr; 23(8):771-7. PubMed ID: 10231138
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [How long should cyclosporin be administered following bone marrow transplantation?].
    Gratwohl A; Tichelli A; Stauffer G; Passweg J; Pless M; Gengenbacher D; Buser U; Signer E; Haberthür C; Gimmi C
    Schweiz Med Wochenschr; 1994 Jan; 124(1-2):44-50. PubMed ID: 8296190
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Reduced-intensity stem cell transplantation using allogeneic peripheral blood stem cells from the same donor for relapsed leukemia after bone marrow transplantation].
    Kuroki F; Goto H; Yanagimachi M; Kajiwara R; Fujii H; Isaki S; Takahashi H; Ikuta K; Yokota S
    Rinsho Ketsueki; 2006 Jul; 47(7):639-44. PubMed ID: 16910574
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Feasibility of early tapering and discontinuation of cyclosporine to intensify the graft-versus-leukemia effect in patients with advanced hematologic neoplasms].
    Fujimaki K; Fujisawa S; Aotsuka N; Saito K; Kanamori H; Matsuzaki M; Takahashi S; Okamoto S; Sakamaki H; Maruta A
    Rinsho Ketsueki; 2001 Sep; 42(9):680-4. PubMed ID: 11680978
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
    Weiss L; Reich S; Slavin S
    Cytokines Cell Mol Ther; 1999 Sep; 5(3):145-52. PubMed ID: 10641572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells.
    Blazar BR; Taylor PA; Boyer MW; Panoskaltsis-Mortari A; Allison JP; Vallera DA
    J Immunol; 1997 Oct; 159(7):3460-73. PubMed ID: 9317145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease.
    Toze CL; Galal A; Barnett MJ; Shepherd JD; Conneally EA; Hogge DE; Nantel SH; Nevill TJ; Sutherland HJ; Connors JM; Voss NJ; Kiss TL; Messner HA; Lavoie JC; Forrest DL; Song KW; Smith CA; Lipton J
    Bone Marrow Transplant; 2005 Nov; 36(9):825-30. PubMed ID: 16151430
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation.
    Hiraoka A; Ohashi Y; Okamoto S; Moriyama Y; Nagao T; Kodera Y; Kanamaru A; Dohy H; Masaoka T;
    Bone Marrow Transplant; 2001 Jul; 28(2):181-5. PubMed ID: 11509936
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The influence of infection early after allogeneic stem cell transplantation on the risk of leukemic relapse and graft-versus-host disease.
    Kim SY; Lee DG; Kim MS; Kim HJ; Lee S; Min CK
    Am J Hematol; 2008 Oct; 83(10):784-8. PubMed ID: 18661492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Female genital tract graft-versus-host disease following allogeneic bone marrow transplantation.
    Spinelli S; Chiodi S; Costantini S; Van Lint MT; Raiola AM; Ravera GB; Bacigalupo A
    Haematologica; 2003 Oct; 88(10):1163-8. PubMed ID: 14555313
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative analysis of clinical outcomes after allogeneic bone marrow transplantation versus peripheral blood stem cell transplantation from a related donor in Japanese patients.
    Tanimoto TE; Yamaguchi T; Tanaka Y; Saito A; Tajima K; Karasuno T; Kasai M; Kishi K; Mori T; Maseki N; Morishima S; Miyakoshi S; Kasai M; Ohno Y; Kim SW; Numata A; Kami M; Takaue Y; Mori S; Harada M
    Br J Haematol; 2004 May; 125(4):480-93. PubMed ID: 15142119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyclosporine-induced autologous graft-versus-host disease in patients with acute myeloid leukemia undergoing non-myeloablative chemotherapy without progenitor cell reinfusion.
    Stein M; Feldman E; Seiter K; Chiao JW; Goff H; Baskind P; Beer M; Ahmed T
    Bone Marrow Transplant; 1999 Nov; 24(10):1073-7. PubMed ID: 10578157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
    Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
    Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
    Johnson BD; Becker EE; Truitt RL
    Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early cyclosporine taper in high-risk sibling allogeneic bone marrow transplants.
    Abraham R; Szer J; Bardy P; Grigg A
    Bone Marrow Transplant; 1997 Nov; 20(9):773-7. PubMed ID: 9384480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.